Please login to the form below

Not currently logged in

Non-muscle-invasive bladder cancer

This page shows the latest Non-muscle-invasive bladder cancer news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca’s Imfinzi fails first-line bladder cancer test

AstraZeneca’s Imfinzi fails first-line bladder cancer test

AZ’s head of oncology José Baselga said that Imfinzi is still in a “comprehensive” phase 3 programme in bladder cancer. ... pre-surgery) bladder cancer treatment, and the POTOMAC study, which include subjects with non-muscle invasive bladder

Latest news

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2015 Deal Watch October 2015

    Immunomic Therapeutics will retain the rights to its LAMP-vax platform for other applications, including cancer immunotherapy. ... MCNA for non-muscle invasive bladder cancer  (BLA filed). Licence. 137. Proteros biostructures/ Merck &Co.

  • Achieving consensus

    Their joint aim: to facilitate uniform use of fluorescence cystoscopy in the diagnosis and follow up of bladder cancer, with the ultimate goal of improved care and better outcomes for patients. ... Despite widespread acceptance of the evidence for

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....